menu search

KMPH / KemPharm: Now A Rare Disease Play, Upgrading To A Buy Rating

KemPharm: Now A Rare Disease Play, Upgrading To A Buy Rating
We initiated KemPharm with a Sell rating in March 2021; since then, the stock has declined >40%, and now the stock is trading at an attractive enterprise value of $130m. AZSTARYS targeting ADHD has been approved, and it no longer contributes much to the stock price at this point. Arimoclomol targeting NPC is the next focus. Read More
Posted: Feb 3 2023, 10:03
Author Name: Seeking Alpha
Views: 112595

KMPH News  

KemPharm: Now A Rare Disease Play, Upgrading To A Buy Rating

By Seeking Alpha
February 3, 2023

KemPharm: Now A Rare Disease Play, Upgrading To A Buy Rating

We initiated KemPharm with a Sell rating in March 2021; since then, the stock has declined >40%, and now the stock is trading at an attractive enterpr more_horizontal

KemPharm, Inc. (KMPH) Q3 2022 Earnings Call Transcript

By Seeking Alpha
November 9, 2022

KemPharm, Inc. (KMPH) Q3 2022 Earnings Call Transcript

KemPharm, Inc. (NASDAQ:KMPH ) Q3 2022 Results Conference Call November 9, 2022 5:00 PM ET Company Participants Nichol Ochsner - Vice President of Inve more_horizontal

KemPharm, Inc. (KMPH) CEO Travis Mickle on Q1 2022 Results - Earnings Call Transcript

By Seeking Alpha
May 12, 2022

KemPharm, Inc. (KMPH) CEO Travis Mickle on Q1 2022 Results - Earnings Call Transcript

KemPharm, Inc. (NASDAQ:KMPH ) Q1 2022 Earnings Conference Call May 12, 2022 5:00 PM ET Company Participants Travis Mickle - Co-Founder, President, CEO more_horizontal

KemPharm, Inc. (KMPH) CEO Travis Mickle on Q4 2021 Results - Earnings Call Transcript

By Seeking Alpha
March 30, 2022

KemPharm, Inc. (KMPH) CEO Travis Mickle on Q4 2021 Results - Earnings Call Transcript

KemPharm, Inc. (KMPH) CEO Travis Mickle on Q4 2021 Results - Earnings Call Transcript more_horizontal

KemPharm To Develop KP1077 As Lead SDX Candidate For Chronic Sleep Disorder

By Benzinga
January 20, 2022

KemPharm To Develop KP1077 As Lead SDX Candidate For Chronic Sleep Disorder

KemPharm Inc (NASDAQ: KMPH) has selected KP1077 for idiopathic hypersomnia (IH) as its lead serdexmethylphenidate (SDX) candidate in the pipeline. Id more_horizontal

KemPharm To Develop KP1077 As Lead SDX Candidate For Chronic Sleep Disorder

By Benzinga
January 20, 2022

KemPharm To Develop KP1077 As Lead SDX Candidate For Chronic Sleep Disorder

KemPharm Inc (NASDAQ: KMPH) has selected KP1077 for idiopathic hypersomnia (IH) as its lead serdexmethylphenidate (SDX) candidate in the pipeline. Id more_horizontal

KemPharm To Develop KP1077 As Lead SDX Candidate For Chronic Sleep Disorder

By Benzinga
January 20, 2022

KemPharm To Develop KP1077 As Lead SDX Candidate For Chronic Sleep Disorder

KemPharm Inc (NASDAQ: KMPH) has selected KP1077 for idiopathic hypersomnia (IH) as its lead serdexmethylphenidate (SDX) candidate in the pipeline. Id more_horizontal


Search within

Pages Search Results: